Standard BioTools
LAB
99 hedge funds and large institutions have $702M invested in Standard BioTools in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 43 increasing their positions, 34 reducing their positions, and 18 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 34
16% more call options, than puts
Call options by funds: $2.86M | Put options by funds: $2.47M
5% less funds holding
Funds holding: 104 → 99 (-5)
11% less capital invested
Capital invested by funds: $788M → $702M (-$85.4M)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$15.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$15.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$14.7M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$8.26M |
| 5 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$6.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pier Capital
Stamford,
Connecticut
|
-$7.47M |
| 2 |
SCM
Sandler Capital Management
New York
|
-$3.99M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$3.48M |
| 4 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
-$3.29M |
| 5 |
CCM
Cupps Capital Management
Chicago,
Illinois
|
-$3.04M |
LAB Hedge Fund Activity: Q3 2014 in Review
99 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2014, worth a combined $702M — down 11% from $788M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LAB and 13 opened new positions — a net loss of 5 holders — while 34 trimmed existing stakes and 43 added.
The largest buyer was Luther King Capital Management (LKCM), opening a new position worth an estimated $15.7M. The largest seller was Pier Capital, exiting entirely with an estimated $7.47M sold.
- 99 institutional investors held Standard BioTools (LAB) as of Q3 2014, down from 104 in Q2 2014.
- Funds reported $702M of Standard BioTools stock for Q3 2014, down 11% quarter-over-quarter.
- 13 funds opened new Standard BioTools positions in Q3 2014 and 18 closed out, a net change of -5 holders.
- The largest Standard BioTools buyer in Q3 2014 was Luther King Capital Management (LKCM), an estimated $15.7M added.
- The largest Standard BioTools seller in Q3 2014 was Pier Capital, an estimated $7.47M sold.
Based on aggregated 13F filings for Q3 2014.